Coherus Biosciences

Coherus Oncology follows a two‑pillar strategy: LOQTORZI is expected to deliver near‑term revenue to fund development of the immune‑resistance–focused programs Tagmokitug (CCR8 antibody) and Casdozokitug (IL‑27 antagonist). Management projects LOQTORZI will reach an annualized revenue of about $175 million by 2026 and quarterly sales of $15 million (2026) and $30–35 million by the end of 2027, which should cover operating costs. Tagmokitug is regarded as the lead candidate with several data readouts from late 2025 through 2026, including full data from the head‑and‑neck study in October 2025. Casdozokitug showed early efficacy in hepatocellular carcinoma (ORR 38%, CR 17%) and is in a randomized trial with data expected by the end of 2025. » Mais em de.investing.com

Coherus BioSciences reported Q1 2026 revenue of $12.31 million, missing the $14.43 million estimate, while EPS of -$0.25 matched expectations. Despite the revenue shortfall, the stock rose 11.43% in after-hours trading to $1.89, driven by optimism about growth opportunities and strategic initiatives. Lead product LOQTORZI achieved 61% year‑over‑year revenue growth; management expects a weather‑related recovery in Q2 and targets quarterly revenues of $15 million by the end of 2026 and $30–35 million for 2027. » Mais em de.investing.com

Under CEO Dennis Lanfear, Coherus BioSciences is making a strategic shift to oncology with an emphasis on immune resistance and is strengthening its pipeline through the acquisition of Surface Oncology and the sale of biosimilar assets. The sale proceeds from UDENYCA generated an upfront payment of $483 million plus expected follow‑on payments, and the company raised an additional $50 million. LOQTORZI revenue rose to $40.8 million in 2025 and is expected to cover sales expenses by 2026 and core operating costs by 2027; clinical data on Tagmokitug and Casdozokitug are considered promising. Coherus is expanding its sales force, pursuing partnerships outside the U.S., and is targeting a mid‑term market share of 70% for LOQTORZI. » Mais em de.investing.com